JP6860558B2 - ソヤサポニンを含有する発毛および/または育毛促進用組成物 - Google Patents
ソヤサポニンを含有する発毛および/または育毛促進用組成物 Download PDFInfo
- Publication number
- JP6860558B2 JP6860558B2 JP2018516767A JP2018516767A JP6860558B2 JP 6860558 B2 JP6860558 B2 JP 6860558B2 JP 2018516767 A JP2018516767 A JP 2018516767A JP 2018516767 A JP2018516767 A JP 2018516767A JP 6860558 B2 JP6860558 B2 JP 6860558B2
- Authority
- JP
- Japan
- Prior art keywords
- hair
- soyasaponin
- composition
- hair growth
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 53
- 230000003779 hair growth Effects 0.000 title claims description 27
- 230000001737 promoting effect Effects 0.000 title claims description 18
- 229930187719 Soyasaponin Natural products 0.000 title description 49
- 210000004209 hair Anatomy 0.000 claims description 57
- KBGJRGWLUHSDLW-UHFFFAOYSA-N acetylsoyasaponin a4 Chemical compound CC(=O)OC1C(OC(C)=O)C(OC(=O)C)COC1OC1C(O)C(OC2C3(CCC4(C)C5(C)CCC6C(C)(CO)C(OC7C(C(O)C(O)C(O7)C(O)=O)OC7C(C(O)C(O)C(CO)O7)OC7C(C(O)C(O)C(CO)O7)O)CCC6(C)C5CC=C4C3CC(C)(C)C2O)C)OCC1O KBGJRGWLUHSDLW-UHFFFAOYSA-N 0.000 claims description 23
- 210000004027 cell Anatomy 0.000 claims description 17
- 230000002500 effect on skin Effects 0.000 claims description 12
- 239000002537 cosmetic Substances 0.000 claims description 11
- 210000003491 skin Anatomy 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 210000004761 scalp Anatomy 0.000 claims description 9
- 239000006210 lotion Substances 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 7
- 239000002674 ointment Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 5
- 239000002453 shampoo Substances 0.000 claims description 4
- 230000001256 tonic effect Effects 0.000 claims description 4
- 230000035755 proliferation Effects 0.000 claims description 3
- 230000001934 delay Effects 0.000 claims 1
- 210000000442 hair follicle cell Anatomy 0.000 claims 1
- 239000002552 dosage form Substances 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 210000003780 hair follicle Anatomy 0.000 description 17
- 201000004384 Alopecia Diseases 0.000 description 16
- 230000003698 anagen phase Effects 0.000 description 12
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 10
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 10
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 10
- 238000007796 conventional method Methods 0.000 description 9
- 230000003676 hair loss Effects 0.000 description 9
- 208000024963 hair loss Diseases 0.000 description 9
- WIURKZVZWYELHL-UHFFFAOYSA-N 2,5-dihydroxy-6-methyl-2,3-dihydropyran-4-one Chemical group CC1=C(O)C(=O)CC(O)O1 WIURKZVZWYELHL-UHFFFAOYSA-N 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 229930182490 saponin Natural products 0.000 description 7
- 235000017709 saponins Nutrition 0.000 description 7
- 150000007949 saponins Chemical class 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- -1 glycoside compound Chemical class 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 244000068988 Glycine max Species 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 231100000360 alopecia Toxicity 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000003778 catagen phase Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000007901 soft capsule Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 230000003797 telogen phase Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000416162 Astragalus gummifer Species 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108010076876 Keratins Proteins 0.000 description 3
- 102000011782 Keratins Human genes 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 3
- 239000003098 androgen Substances 0.000 description 3
- 201000002996 androgenic alopecia Diseases 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000013538 functional additive Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229960003632 minoxidil Drugs 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- YOQAQNKGFOLRGT-UXXABWCISA-N (3beta,22beta)-olean-12-ene-3,22,24-triol Chemical compound C1C[C@H](O)[C@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)[C@H](O)CC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C YOQAQNKGFOLRGT-UXXABWCISA-N 0.000 description 2
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 2
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 2
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- URRZRRQMNMZIAP-UHFFFAOYSA-N Kudzusapogenol C Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)C(O)CC3(C)CCC21C URRZRRQMNMZIAP-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 208000004631 alopecia areata Diseases 0.000 description 2
- 206010068168 androgenetic alopecia Diseases 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- MADZMXIFUWFDJK-AEARDBQCSA-N soyasapogenol B Natural products CC1(C)C[C@@H](O)[C@]2(C)CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O[C@@H]6O[C@@H]([C@@H](O)[C@H](O)[C@H]6O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O)C(=O)O)[C@](C)(CO)[C@@H]5CC[C@@]34C)[C@H]2C1 MADZMXIFUWFDJK-AEARDBQCSA-N 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- CDDWAYFUFNQLRZ-KJVHGCRFSA-N (3beta,21beta,22beta)-olean-12-ene-3,21,22,24-tetrol Chemical compound C([C@@]12C)C[C@H](O)[C@](C)(CO)[C@@H]1CC[C@]1(C)[C@@H]2CC=C2[C@@H]3CC(C)(C)[C@@H](O)[C@@H](O)[C@]3(C)CC[C@]21C CDDWAYFUFNQLRZ-KJVHGCRFSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010004542 Bezoar Diseases 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- FTPPTNQVRLPEAE-UHFFFAOYSA-N Soyasapogenol-E Natural products CC1(C)CC(=O)C2(C)CCC3C(=CCC4C3(C)CCC5C(C)(CO)C(O)CCC45C)C2(C)C1 FTPPTNQVRLPEAE-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000035597 cooling sensation Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000005195 occipital scalp Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000003405 preventing effect Effects 0.000 description 1
- 230000003658 preventing hair loss Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000021487 ready-to-eat food Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000004037 social stress Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- CDDWAYFUFNQLRZ-UHFFFAOYSA-N soyasapogenol A Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)C(O)C(O)C3(C)CCC21C CDDWAYFUFNQLRZ-UHFFFAOYSA-N 0.000 description 1
- FNRBOAGVUNHDIL-LMZUXBMISA-N soyasapogenol E Chemical compound C([C@@]12C)C[C@H](O)[C@](C)(CO)[C@@H]1CC[C@]1(C)[C@@H]2CC=C2[C@@H]3CC(C)(C)CC(=O)[C@]3(C)CC[C@]21C FNRBOAGVUNHDIL-LMZUXBMISA-N 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000003515 testosterones Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Steroid Compounds (AREA)
Description
本発明の組成物の効能を実験するために、ソヤサポニンAaは、Chengdu Biopurity Phytochemicals Ltd.で購買して試験に使用した。
ソヤサポニンAaが血管形成に必要な成長因子で毛髪の成長期に移動するのに必要な成長因子である血管内皮成長因子(Vascular endothelial growth factor;VEGF)を発現させる程度を評価するために、生体外(in vitro)システムを適用してソヤサポニンAaを処理後、活性を評価した。前記実験のために、47歳男性の毛乳頭真皮細胞(Dermal Papilla Cell;DPC)(P.11)4×105個の細胞を12−ウェルプレート(well plate)にシーディング(seeding)し、10%FBS(fetal bovine serum)を含有するDMEM(Dulbecco’s modified Eagle’s medium;Gibco BRL、Gaithersburg、MD、USA)で一夜培養した。培養後、ソヤサポニンAaを20ppmに処理した。陰性対照群としては、DMSOを使用した。24時間後、ソヤサポニンAaが処理された混合液を収集(soup collect)し、VEGF ELISA(Vascular endothelial growth factor Enzyme−Linked Immunosorbent Assay;R&D biosystems)を使用してソヤサポニンAaによるVEGFの発現程度を確認した。そして、その結果を下記表2に示した。
毛髪を構成するケラチンタンパク質は、毛根部ケラチン形成細胞(keratinocyte)で生成され、このケラチン形成細胞は、毛乳頭細胞から分化する。従って、本発明に係るソヤサポニンAaが毛乳頭細胞の活性を促進するならば、それから分化するケラチン形成細胞の活性を促進させることができ、さらには毛髪生成を促進できるだろう。
先ず、本発明においては、ヒト毛乳頭細胞(Human dermal papilla cell、ソウル大学校病院皮膚科のクォン・オサン教授から入手)細胞株を使用した。前記細胞株は、10%FBSが含有されたDMEM(Dulbecco’s modified Eagle’s medium;Gibco BRL、Gaithersburg、MD、USA)を使用して、5%CO2、37℃が維持されるインキュベーターで24時間培養した後、ソヤサポニンAaを1ppm、10ppmおよび20ppmでそれぞれ処理した。陰性対照群としては、DMSOを使用した。試験物質を処理した後、24時間経過後にWST−1キット(Roche)を使用して細胞増殖能(%)を測定した。その結果を下記表3に示した。
本発明の実際の人体毛包器官での毛髪成長促進能を確認する実験を実施した。
55歳男性の後頭部頭皮組織から毛包器官を一つずつ分離してWilliam’s E培地〔L−グルタミン(2mM)、インスリン(10μg/ml)、ヒドロコルチゾン(40ng/ml)、抗生剤(1%)、抗真菌剤(1%)含有〕に培養した。培養後3日目に成長が起こった毛包を選別して3mmに切り、選別した毛包組織に対して、薬物を処理していない場合を対照群とし、ソヤサポニンAaを1ppm、5ppmおよび10ppmでそれぞれ処理した。そして、処理してから8日後、毛髪長さ測定をそれぞれ進行した。その結果を下記表4に示した。
下記表5に記載の組成によって常法でヘアトニックを製造した。
下記表6に記載の組成によって常法でヘアローションを製造した。
下記表7に記載の組成によって常法で毛髪栄養化粧水を製造した。
下記表8に記載の組成によって常法でヘアシャンプーを製造した。
下記表9に記載の組成によって常法でヘアリンスを製造した。
下記表10に記載の組成によって常法で軟膏を製造した。
ソヤサポニンAa50mg、L−カルニチン80〜140mg、大豆油180mg、パーム油2mg、植物性硬化油8mg、黄鉛4mgおよびレシチン6mgを混合し、常法によって1カプセル当たり400mgずつ充填して軟質カプセルを製造した。
ソヤサポニンAa50mg、ガラクトオリゴ糖200mg、乳糖60mgおよび麦芽糖140mgを混合し、流動層乾燥機を使用して顆粒した後、糖エステル(sugar ester)6mgを添加して打錠し、錠剤を製造した。
ソヤサポニンAa50mg、無水結晶ブドウ糖250mgおよびデンプン550mgを混合し、流動層顆粒機を使用して顆粒に成形した後、袋に充填した。
ソヤサポニンAa50mg、ブドウ糖10g、クエン酸0.6gおよび液状オリゴ糖25gを混合した後、精製水300mlを加えて瓶に充填した。以後、130℃で4〜5秒間殺菌して飲料を製造した。
Claims (6)
- ソヤサボニンAaを有効成分とし、当該ソヤサポニンAaは組成物の総重量に対して0.001〜10重量%の量で含有されることを特徴とする発毛または育毛促進用組成物。
- 前記組成物は、毛包細胞の退行を遅延させることを特徴とする請求項1に記載の組成物。
- 前記組成物は、毛乳頭細胞の増殖を促進させることを特徴とする請求項1に記載の組成物。
- 前記組成物は、皮膚外用剤であることを特徴とする請求項1に記載の組成物。
- 請求項1〜4のいずれか一項に記載の組成物を含む、毛髪または頭皮用化粧品。
- 前記化粧品は、シャンプ一、ヘアトリートメント、スカルプトリートメント、ヘアエッセンス、ヘアパック、ヘアクリーム、ヘアローション、ヘアトニックまたは軟膏剤の形態に剤形化されたものであることを特徴とする請求項5に記載の化粧品。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150137532A KR102406000B1 (ko) | 2015-09-30 | 2015-09-30 | 소야사포닌을 함유하는 발모 및/또는 육모 촉진용 조성물 |
KR10-2015-0137532 | 2015-09-30 | ||
PCT/KR2016/010893 WO2017057910A1 (ko) | 2015-09-30 | 2016-09-29 | 소야사포닌을 함유하는 발모 및/또는 육모 촉진용 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018534268A JP2018534268A (ja) | 2018-11-22 |
JP6860558B2 true JP6860558B2 (ja) | 2021-04-14 |
Family
ID=58424150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018516767A Active JP6860558B2 (ja) | 2015-09-30 | 2016-09-29 | ソヤサポニンを含有する発毛および/または育毛促進用組成物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US10617622B2 (ja) |
EP (1) | EP3357486B1 (ja) |
JP (1) | JP6860558B2 (ja) |
KR (1) | KR102406000B1 (ja) |
CN (1) | CN108135820A (ja) |
HK (1) | HK1254449A1 (ja) |
TW (1) | TWI738671B (ja) |
WO (1) | WO2017057910A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020185382A1 (en) * | 2019-03-08 | 2020-09-17 | The Procter & Gamble Company | Structured aqueous compositions having dispersed liquid benefit agent droplets |
CN110101153B (zh) * | 2019-04-22 | 2021-08-31 | 太和县金意成毛发制品有限公司 | 一种修复假发中角质蛋白活性的处理方法 |
CN115209867B (zh) * | 2020-03-05 | 2024-04-09 | 一丸自然美健有限公司 | 毛发生长促进用和/或白发改善用组合物 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6293217A (ja) * | 1985-10-18 | 1987-04-28 | Shiseido Co Ltd | 養毛料 |
KR910008736B1 (ko) * | 1989-06-13 | 1991-10-19 | 태평양화학주식회사 | 4급암모니움-치환된 사포닌 에테르 유도체 및 그 제조방법 |
JPH03287516A (ja) * | 1989-07-17 | 1991-12-18 | Daiko Sangyo:Kk | 発毛剤 |
JP2781626B2 (ja) * | 1989-12-18 | 1998-07-30 | 鐘紡株式会社 | 可溶化型透明化粧料 |
US5723149A (en) * | 1990-11-21 | 1998-03-03 | Lvmh Recherche | Use of medicago saponins for the preparation of cosmetic or pharmaceutical compositions, especially dermatological compositions, promoting renewal of the epidermis, stimulating hair regrowth or delaying hair loss |
FR2669225B1 (fr) * | 1990-11-21 | 1993-11-12 | Lvmh Recherche Gie | Utilisation de saponines de medicago pour la preparation de compositions cosmetiques ou pharmaceutiques, notamment dermatologiques. |
FR2695561B1 (fr) * | 1992-09-17 | 1994-12-02 | Lvmh Rech Gie | Composition cosmétique ou dermatologique contenant au moins une saponine de type ginsenoside, et ses applications, notamment pour le soin des cheveux. |
JP3407064B2 (ja) * | 1993-11-13 | 2003-05-19 | サンスター株式会社 | 育毛養毛用食品 |
JP3287516B2 (ja) | 1994-06-24 | 2002-06-04 | アルプス電気株式会社 | プリンタの紙送り装置 |
JPH10218745A (ja) * | 1997-02-12 | 1998-08-18 | Rashieru Seiyaku Kk | シャンプー組成物 |
JPH10265347A (ja) * | 1997-03-26 | 1998-10-06 | Shiseido Co Ltd | 毛髪成長期延長剤 |
JPH11343226A (ja) * | 1998-03-31 | 1999-12-14 | Shiseido Co Ltd | 皮膚賦活用組成物 |
FR2779058B1 (fr) * | 1998-05-29 | 2003-02-21 | Dior Christian Parfums | Utilisation d'au moins une saponine ou un sapogenol cosmetiquement acceptable, comme agent cosmetique destine a augmenter la quantite de collagene iv dans la jonction dermo-epidermique |
JP3798927B2 (ja) * | 1998-10-26 | 2006-07-19 | 株式会社資生堂 | 血行促進皮膚外用剤 |
EP0998907B1 (en) | 1998-10-26 | 2004-01-14 | Shiseido Company, Ltd. | Hair tonic composition comprising adenosine |
JP2006213649A (ja) * | 2005-02-03 | 2006-08-17 | Osaka Yakuhin Kenkyusho:Kk | 大豆サポニンからなる細胞賦活剤、コラーゲン産生促進剤及び抗酸化剤、並びに該細胞賦活剤、該コラーゲン産生促進剤及び/又は該抗酸化剤を含有する化粧料原料、並びに該化粧料原料を含有する化粧料組成物 |
CN101392016B (zh) * | 2008-10-07 | 2013-01-02 | 上海同田生物技术股份有限公司 | 一种高纯度大豆皂苷a和b的制备方法 |
JP2010222273A (ja) * | 2009-03-23 | 2010-10-07 | B & C Laboratories Inc | 養毛剤組成物 |
JP2012031132A (ja) * | 2010-07-02 | 2012-02-16 | Fancl Corp | 疲労改善組成物 |
KR101274029B1 (ko) * | 2011-01-06 | 2013-06-12 | (주)대덕바이오 | 사포닌 Rd와 Re를 유효성분으로 포함하는 발모용 조성물 |
KR20140037107A (ko) * | 2011-06-28 | 2014-03-26 | 제이-오일 밀스, 인코포레이티드 | 소야 사포게놀 조성물 |
EP2878295A4 (en) * | 2012-07-24 | 2015-12-23 | J Oil Mills Inc | COMPOSITION |
KR20140039809A (ko) * | 2012-09-25 | 2014-04-02 | 명지대학교 산학협력단 | 소야사포닌 Aa를 포함하는 비만 또는 지질 관련 대사성 질환 예방 또는 치료용 조성물 |
KR102061716B1 (ko) * | 2013-08-30 | 2020-01-02 | (주)아모레퍼시픽 | 21-o-안젤로일티아사포제놀 e3을 포함하는 발모 또는 육모 촉진용 조성물 |
-
2015
- 2015-09-30 KR KR1020150137532A patent/KR102406000B1/ko active IP Right Grant
-
2016
- 2016-09-29 US US15/764,625 patent/US10617622B2/en active Active
- 2016-09-29 WO PCT/KR2016/010893 patent/WO2017057910A1/ko active Application Filing
- 2016-09-29 JP JP2018516767A patent/JP6860558B2/ja active Active
- 2016-09-29 CN CN201680057156.0A patent/CN108135820A/zh active Pending
- 2016-09-29 EP EP16852056.7A patent/EP3357486B1/en active Active
- 2016-09-30 TW TW105131593A patent/TWI738671B/zh active
-
2018
- 2018-10-23 HK HK18113534.6A patent/HK1254449A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JP2018534268A (ja) | 2018-11-22 |
HK1254449A1 (zh) | 2019-07-19 |
KR20170038314A (ko) | 2017-04-07 |
KR102406000B1 (ko) | 2022-06-08 |
WO2017057910A1 (ko) | 2017-04-06 |
CN108135820A (zh) | 2018-06-08 |
TW201711678A (zh) | 2017-04-01 |
EP3357486B1 (en) | 2021-03-31 |
EP3357486A4 (en) | 2019-03-20 |
US20180303737A1 (en) | 2018-10-25 |
US10617622B2 (en) | 2020-04-14 |
TWI738671B (zh) | 2021-09-11 |
EP3357486A1 (en) | 2018-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107530258B (zh) | 用于促进毛发生长或毛发修复和用于抗炎的组合物 | |
KR102598855B1 (ko) | 텍토리게닌을 함유하는 여성형 탈모의 개선용 조성물 | |
JP6860558B2 (ja) | ソヤサポニンを含有する発毛および/または育毛促進用組成物 | |
US9636289B2 (en) | Composition for preventing or treating hair loss or promoting hair growth comprising secoiridoid glucoside derivatives | |
JP6339189B2 (ja) | 発毛および育毛促進用組成物 | |
KR102598872B1 (ko) | 모린을 함유하는 여성형 탈모의 개선용 조성물 | |
KR101824497B1 (ko) | 피토에스트로겐을 유효성분으로 포함하는 탈모방지 및 모발 성장 촉진용 조성물 | |
KR101935492B1 (ko) | 야라야라를 유효성분으로 포함하는 탈모 방지 또는 발모 촉진용 조성물 | |
KR102591604B1 (ko) | 코나루스 세미데칸드러스 잭. 추출물을 포함하는 탈모 예방 또는 치료용 약학적 조성물 | |
KR20190046685A (ko) | 노나날을 유효성분으로 포함하는 탈모 방지 또는 발모 촉진용 조성물 | |
KR102061716B1 (ko) | 21-o-안젤로일티아사포제놀 e3을 포함하는 발모 또는 육모 촉진용 조성물 | |
KR102115667B1 (ko) | 아이론을 유효성분으로 포함 하는 탈모 방지 또는 발모 촉진용 조성물 | |
US10265299B2 (en) | Composition for promoting hair growth and/or hair restoration containing psoralidin | |
KR20190046696A (ko) | 펠란드렌을 유효성분으로 포함하는 탈모 방지 또는 발모 촉진용 조성물 | |
KR102360927B1 (ko) | 런시나트사이드를 포함하는 탈모 방지 및 발모 촉진용 조성물 | |
KR102600558B1 (ko) | 아트라릭산을 포함하는 발모 촉진 및 탈모 방지용 조성물 | |
KR20170082026A (ko) | 진세노사이드 f5를 포함하는 탈모 방지 또는 육모 촉진용 조성물 | |
KR20220049196A (ko) | 두피 개선 및 탈모 완화용 펩타이드 조성물 | |
KR20190046695A (ko) | 수베르산을 유효성분으로 포함하는 탈모 방지 또는 발모 촉진용 조성물 | |
CN118055940A (zh) | 具有预防脱发或促进毛发生长的活性的肽及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190611 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200312 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200407 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200707 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20201027 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210128 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20210128 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20210208 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20210216 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210302 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210326 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6860558 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |